“I just immediately thought, ‘What a wonderful life I’ve had,’ ” the 67-year-old said ...

The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

Adjuvant atezolizumab combined with mFOLFOX6 halved the risk of disease recurrence or death in patients with resected stage III mismatch repair–deficient colon cancer in the phase 3 ATOMIC trial.

Colon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than 50. While colon cancer screening has helped ...

The FDA has approved atezolizumab plus chemotherapy as an adjuvant treatment for patients aged 2 years and older with stage ...

Colorectal cancer in young people is often diagnosed at an advanced stage, with researchers finding most patients age 21 or ...

Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...

Add Yahoo as a preferred source to see more of our stories on Google. Five years ago, Tim Cannon, a cancer doctor in Virginia, saw that his colon cancer patients were getting younger and their cancer ...

The FDA has approved atezolizumab with chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase III ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...